Search results for "Place"

showing 10 items of 3222 documents

Effectiveness of oral health education versus nicotine replacement therapy for tobacco cessation- a parallel randomized clinical trial.

2015

Background: India has millions of tobacco users. It is the leading cause of deaths due to oral cancer and hence needs effective strategies to curb it. Hence the aim of present study was to evaluate and compare the effectiveness of Oral Health Education (OHE) and Nicotine Replacement Therapy (NRT) in tobacco cessation. Material and Methods: The clinical trial consisted of Manohar Lal Kapoor (MLK) factory workers (n= 40) giving history of tobacco consumption (smoking/smokeless) within past 30 days. They were randomized into OHE (n=20) and NRT (n=20) groups. Baseline evaluation (demographic, smoking/ smokeless behaviour) was done. Fagerstrom test was used for Nicotine Dependence (FTND) and to …

medicine.medical_specialtyOdontologíalaw.inventionNicotine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawTobacco usersInternal medicinemental disordersmedicineGeneral Dentistrybusiness.industryOral health educationResearch030206 dentistryNicotine replacement therapy:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludNicotine AddictionCommunity and Preventive DentistryClinical trialchemistry030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASCotininebusinessmedicine.drugJournal of clinical and experimental dentistry
researchProduct

Process-Optimized Minimally Invasive Total Hip Replacement via a Direct Anterior Approach with Navigation Control of Leg Length and Offset

2013

The purpose of this study was to analyze a new concept of using the minimally invasive direct anterior approach (DAA) in total hip replacement (THR) in combination with a leg positioner (Rotex-Table) and a modified retractor system (Condor). To control leg length and offset, the navigation system OrthoPilot® (B. Braun, Aesculap) or the Medacta system was used. We retrospectively evaluated the first 100 primary THRs performed with this new concept between 2009 and 2010, regarding the surgical data as well as the radiological and clinical outcome (Hip Disability and Osteoarthritis Outcome score, HOOS). All surgeries were perfomed following a standardized operation technique including navigati…

medicine.medical_specialtyOffset (computer science)business.industryTotal hip replacementNavigation systemOsteoarthritismedicine.diseaseSurgeryRetractorRadiological weaponmedicineAnterior approachbusinessBody mass index
researchProduct

Risk of Parkinson disease in women: Effect of reproductive characteristics

2004

Objective: To investigate the association between some fertile life characteristics and Parkinson disease (PD) in women. Methods: Women affected by PD and control subjects were matched one to one by age (±2 years). One hundred thirty-one women with idiopathic PD and 131 matched control subjects were interviewed. Controls were randomly selected from the resident list of the same municipality of residence of cases. All subjects had a Mini-Mental State Examination score of ≥24. Cumulative length of pregnancies, age at menarche, age and type of menopause, and estrogen use before and after menopause were investigated in cases and controls through a structured questionnaire. Models of matched pai…

medicine.medical_specialtyOvariectomySurgical MenopauseRisk FactorsSurveys and QuestionnairesmedicineHumansAge of OnsetReproductive HistoryAgedMenarcheUnivariate analysisLife lengthbusiness.industryObstetricsEstrogen Replacement TherapyCase-control studyEstrogensParkinson DiseaseOdds ratioMiddle Agedmedicine.diseaseSurgeryMenopauseParityItalyCase-Control StudiesMenarcheFemaleNeurology (clinical)MenopauseAge of onsetbusiness
researchProduct

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

2017

BACKGROUNDPatients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.METHODSWe performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were …

medicine.medical_specialtyPARALLEL-GROUPPopulationPlacebo-controlled studyPNEUMONIA RISKPlaceboPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMaintenance therapyInternal medicineEosinophilicmedicineINHALED FLUTICASONE FUROATE030212 general & internal medicineeducationCOPDeducation.field_of_studyIntention-to-treat analysisCOPD ASSESSMENT TESTSPUTUM EOSINOPHILIAbusiness.industryGeneral MedicineRANDOMIZED CONTROLLED-TRIALBLOOD EOSINOPHILSmedicine.diseaseSECONDARY ANALYSIS030228 respiratory systemImmunologybusinessMepolizumabmedicine.drug
researchProduct

Comparing medical treatments for Crohn’s disease

2013

The drugs available for inflammatory bowel disease are aminosalicylates, antibiotics, steroids, immunosuppressors and biologics. The effectiveness of these drugs has been evaluated in many randomized clinical trials, mainly versus placebo. Few studies have been conducted comparing the different drugs among themselves, owing to the methodological problems raised by comparative trials, such as sample size and blindness. This review focuses mainly on the randomized clinical trials that have compared different treatments. Of course comparisons are mainly between drugs used in a particular setting (mild, moderate and severe disease). However, on many occasions there is no homogeneity in these cl…

medicine.medical_specialtyPathologymedicine.drug_classAntibioticsAlternative medicineSevere diseasePlaceboInflammatory bowel diseaselaw.inventionBiological FactorsCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAzathioprineIntestinal FistulaSecondary PreventionmedicineHumansBudesonideRandomized Controlled Trials as TopicCrohn's diseasebusiness.industryProbioticsHealth Policymedicine.diseaseAnti-Bacterial AgentsAminosalicylic AcidsMethotrexateSample size determinationbusinessJournal of Comparative Effectiveness Research
researchProduct

Deflazacort in Duchenne dystrophy: Study of long-term effect

1994

A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P < 0.01), in rising from a chair, Gower's maneuver, and walking (P < 0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P < 0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P < 0.02), and grade and time of Gower's maneuver (P < 0.05) were found. The mea…

medicine.medical_specialtyPatient DropoutsTime Factorsmedicine.drug_classPhysiologyDuchenne muscular dystrophymedicine.medical_treatmentMotor ActivityPlaceboMuscular Dystrophieslaw.inventionCellular and Molecular NeuroscienceDouble-Blind MethodRandomized controlled trialPregnenedioneslawPhysiology (medical)medicineHumansChildGaitChemotherapybusiness.industryMusclesAnti-Inflammatory Agents Non-SteroidalBody Weightmedicine.diseaseSurgeryClinical trialDeflazacortAnesthesiaCorticosteroidNeurology (clinical)medicine.symptombusinessWeight gainFollow-Up Studiesmedicine.drugMuscle &amp; Nerve
researchProduct

OC-87 Gaucher disease in romania – baseline characteristics, specific diagnosis. treatment and outcome

2017

Gaucher disease is a autosomal recessive inherited monogenic disease caused by beta-glucocerebrosidase deficiency. Clinically, there are three types: type 1 (non-neuronopathic), type 2 (acute neuronopathic) and type 3 (chronic neuronopathic), in 92%, 1% and respectively 7% of patients. Specific diagnosis has been possible in Romania since 1997 and enzyme replacement therapy since 2002. The aim of the study is to present the epidemiologic, clinical and molecular data of the Romanian patients with Gaucher disease ant their evolution. Patients and methods Seventy-nine patients (76 patients with Gaucher disease type 1 and 3 patients with Gaucher disease type 3; F/M=1.37/1) were evaluated clinic…

medicine.medical_specialtyPediatricsBone densityImigluceraseBone diseasebusiness.industryIncidence (epidemiology)medicine.medical_treatmentSplenectomyPrevalenceEnzyme replacement therapyDiseasemedicine.diseaseGastroenterologyInternal medicineMedicinebusinessmedicine.drugOral Communications
researchProduct

Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (…

2016

Background: RES reduced exacerbation frequency and improved lung function and asthma control in pts with inadequately controlled asthma and elevated blood eosinophils (EOS) in two PBO-controlled, phase 3 trials (Castro et al. Lancet Resp Med 2015). Aims/objectives: To determine the efficacy of RES in asthma pts stratified by GINA Step 4 (G4) and Step 5 (G5) categories of asthma severity. Methods: Pooled data from two 52-week, PBO-controlled trials of RES (3mg/kg IV Q4W) in pts with inadequately controlled asthma and blood EOS ≥400/µL on inhaled corticosteroid (ICS) ± another controller; primary results have been reported. Current analysis includes pts stratified by G4 (medium/high-dose ICS …

medicine.medical_specialtyPediatricsExacerbationbusiness.industrymedicine.drug_classEosinophilic asthmaPlaceboRate ratiomedicine.diseaserespiratory tract diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemReslizumabInternal medicineAsthma controlMedicineCorticosteroid030212 general & internal medicinebusinessmedicine.drugAsthma5.1 Airway Pharmacology and Treatment
researchProduct

987 Emipediology and Morbidity of Late Preterm Neonates in Correlation with Maternal Risk Factors in Hessen, Germany

2012

Short and long term morbidity in late preterm neonates (LP) and their correlation to maternal risk factors are relevant as shown in multiple studies in North America and European countries. Epidemiological studies showed an increase in LP birth over time. Corresponding data for Germany have not yet been published. Our goal was to evaluate the epidemiology of LP over a 7 year period and the correlation to potential maternal risk factors in Hessen, Germany. Data was collected from the perinatal und neonatal quality assurance in Hessen form 2001 to 2007. For some calculations the two data sets were merged. Overall the data sets of 360.000 births and 44.000 neonatal hospitalizations were availa…

medicine.medical_specialtyPediatricsMaternal risk factorsbusiness.industryMaternal morbidityPlacental insufficiencymedicine.diseaseObesityGestational diabetesCorrelationPediatrics Perinatology and Child HealthEpidemiologymedicineLate pretermbusinessArchives of Disease in Childhood
researchProduct

Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder

2015

Importance Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with high prevalence in adulthood. There is a recognized need to assess the efficacy of psychotherapy in adult ADHD. Objective To evaluate the efficacy of cognitive behavioral group psychotherapy (GPT) compared with individual clinical management (CM) and that of methylphenidate hydrochloride compared with placebo. Design, Setting, and Participants Prospective, multicenter, randomized clinical trial of 18- to 58-year-old outpatients with ADHD from 7 German study centers. Patients were recruited between January 2007 and August 2010, treatment was finalized in August 2011, and final follow-up assessmen…

medicine.medical_specialtyPediatricsMethylphenidatemedicine.medical_treatmentMedizinmedicine.diseasePlacebo030227 psychiatry3. Good healthlaw.inventionGroup psychotherapyCognitive behavioral therapy03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineRandomized controlled triallawClinical Global ImpressionmedicineAttention deficit hyperactivity disorderMethylphenidate HydrochloridePsychiatryPsychology030217 neurology & neurosurgerymedicine.drugJAMA Psychiatry
researchProduct